You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沛嘉醫療-B(09996.HK):國家藥監局批准Syphonet®取栓支架註冊申請
格隆匯 02-16 16:57

格隆匯2月16日丨沛嘉醫療-B(09996.HK)宣佈,於2022年2月11日,集團收到國家藥品監督管理局(「國家藥監局」)對Syphonet®取栓支架(先前英文名為Shenyi®)註冊申請的批准,使其成為集團第11個獲國家藥監局批准的神經介入產品。

Syphonet®取栓支架是由加奇生物有限公司("加奇生物",公司全資附屬公司)所開發的技術領先產品,基於我們對創新的不懈追求及對臨牀需求的清晰理解。該產品的獨特遠端抓捕籃設計,能有效防止碎栓逃逸,有助於血栓的清除。支架設計具有優化的徑向支撐力,即使在彎曲血管中也能保持完整管腔。支架通體顯影,全程可視化操作,為術者提供了良好的視覺反饋。Syphonet®取栓支架提供多種規格,全系列兼容0.017in微導管。良好的兼容性將提高到位成功率,減少手術的時間。

Syphonet®取栓支架的註冊獲批上市,標誌着加奇生物進一步豐富了缺血類腦卒中解決方案的產品管線,涵蓋了Syphonet®取栓支架、Tethys®中間導引導管、Presgo®微導絲及Presgo®微導管。隨着今年Tethys AS®血栓抽吸導管及Fluxcap®球囊導引導管的陸續推出,加奇生物將在器械取栓術式方面為術者提供更為全面的解決方案。術者可根據患者的臨牀表現,選擇加奇生物不同的產品組合,滿足不同術式的治療需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account